基因重组人粒细胞集落刺激因子在肿瘤大剂量联合化疗中的临床应用研究

Clinical effect of recombinant human granulocyte colony-stimulating factor on leukopenia induced by high dosage combined chemotherapy in cancer patients

目的 观察基因重组人粒细胞集落刺激因子 (rhG CSF)在肿瘤大剂量联合化疗中预防白细胞减少症的疗效。方法 全组病人 16 7例 ,采用自身对照 ,以第一周期为对照周期 ,第二周期为治疗周期 ,在治疗周期末次给药后 48小时起 ,皮下注射rhG CSF 75 μg/d。 结果 化疗后白细胞降低恢复至正常水平以上所需的时间治疗周期显著缩短 (约 11天 ) ,白细胞的下降程度治疗周期显著优于对照周期 ,治疗周期感染的发生率亦显著低于对照周期。结论 rhG CSF的应用可有效预防白细胞减少症的发生及其程度 ,有力支持肿瘤大剂量联合化疗的进行。

Objective To observe the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukopenia induced by high-dosage combined chemotherapy.Methods The study group consisted of 167 patients.Each patient received two cycles treatment,and the same chemotherapy regimen was used in every cycle.Chemotherapy alone was used in the first cycle(control cycle),and chemotherapy combined with rhG-CSF was used in the second cycle (treatment cycle).rhG-CSF 75 μg/d was subcutaneous injected after 48 hours at the end of the chemotherapy for three to five days.Results The mean time of the patients with leukopenia recovered to normal was 22.3±8.9 days in control cycle and 10.9±5.7 days in treatment cycle (P<0.01).The treatment cycle was better than control cycle in the degree of the number of white blood cell reduction after chemotherapy.The rate of infection was lower significantly in treatment cycle than control cycle(P<0.01).Conclusion These results reveal that rhG-CSF can decrease significantly the incidence of leukopenia and support strongly the completion of high-dosage combined chemotherapy.